Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation

NCT00312039 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Elvucitabine
DRUG: Lamivudine

Sponsor

Alexion Pharmaceuticals, Inc.

Collaborators

[object Object]